How has Sarepta Therapeutics, Inc.'s other commercial liabilities changed year-over-year?

Sarepta Therapeutics, Inc.'s other commercial liabilities decreased by 22.8% year-over-year, from $391.65M to $302.37M.

What is the long-term trend for Sarepta Therapeutics, Inc.'s other commercial liabilities?

Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s other commercial liabilities has grown at a 13.2% compound annual growth rate (CAGR), from $193.55M to $359.66M.

Sarepta Therapeutics, Inc. SRPT Other Commercial Liabilities

Other Commercial Liabilities at other companies

Capricor TherapeuticsCAPR

——

Catalyst PharmaceuticalCPRX

——

uniQureQURE

——

Edgewise Therapeutics, Inc.EWTX

——

CRISPR TherapeuticsCRSP

——

Ultragenyx PharmaceuticalRARE

——

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.82B-63.1%

Enterprise value$1.56B-67.2%

P/S0.8×—

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s other commercial liabilities?: Sarepta Therapeutics, Inc. (SRPT) reported other commercial liabilities of $302.37M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s other commercial liabilities changed year-over-year?: Sarepta Therapeutics, Inc.'s other commercial liabilities decreased by 22.8% year-over-year, from $391.65M to $302.37M.
What is the long-term trend for Sarepta Therapeutics, Inc.'s other commercial liabilities?: Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s other commercial liabilities has grown at a 13.2% compound annual growth rate (CAGR), from $193.55M to $359.66M.